Search the Newsreel

GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts

GH Research PLC (NASDAQ:GHRS) has received an average rating of "Moderate Buy" from analysts, with ten out of twelve recommending a buy and an average 12-month price target of $45.00 against a current price of $28.19. Despite beating quarterly earnings estimates, analysts foresee continued …

GH Research PLC (GHRS) director receives 2,202 options at $0.025 strike

GH Research PLC director Dermot John Hanley was granted 2,202 share options with an exercise price of $0.025 per share. These options vested immediately but are not exercisable until August 11, 2028, and will expire on August 11, 2033. Following this transaction, Hanley directly …

GH Research PLC (GHRS) director receives 2,202 fully vested share options

GH Research PLC director Duncan Moore was granted 2,202 fully vested share options on August 11, 2026, with an exercise price of $0.0250 per ordinary share and an expiration date of August 11, 2033. Although immediately vested, these options are not exercisable until August …

GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer

GH Research PLC (GHRS) director Michael Forer received two grants of share options totaling 102,202 Ordinary Shares, both with an exercise price of $0.0250 per share and expiring on August 11, 2033. One grant of 2,202 options is immediately vested but not exercisable until …

FY2026 EPS Estimates for GH Research Boosted by Analyst

GH Research (GHRS) Looks Pricey Following Wider Losses In Its Latest Earnings Report

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

GH Research PLC recently reported a significant increase in its net loss for Q2 2026 and the first half of 2026, with basic and diluted loss per share rising to US$0.23. This widening loss and higher cash burn are prompting investors to re-evaluate the …

Trading the Move, Not the Narrative: (GHRS) Edition

This article provides an AI-driven analysis for Gh Research Plc (NASDAQ: GHRS), highlighting strong sentiment across all horizons and identifying an exceptional risk-reward short setup. It details three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide traders. The …

H.C. Wainwright reiterates GH Research stock rating on FDA progress

H.C. Wainwright has reiterated a Buy rating and a $65.00 price target for GH Research PLC (NASDAQ:GHRS), following the company's progress with the FDA regarding its GH001 drug. The firm noted that GH Research's chemistry, manufacturing and controls, and device plans appear Phase 3 …

GH Research (NASDAQ:GHRS) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

GH Research (NASDAQ:GHRS) Upgraded at Wall Street Zen

Wall Street Zen has upgraded GH Research (NASDAQ:GHRS) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a target price of $42.78. The company recently reported a quarterly loss of $0.23 per share, outperforming the expected …

GH Research PLC (GHRS) Stock News Today

This article from TradingKey provides current stock information for GH Research PLC (GHRS), including its latest stock price, market capitalization, and a note indicating that more news is coming soon. As of the close on August 7th, the stock was trading at $30.270, with …

GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Cantor Fitzgerald has increased its price target for GH Research (NASDAQ:GHRS) from $35 to $40, maintaining an "overweight" rating and suggesting a potential upside of over 30%. While overall analyst sentiment is positive with a "Moderate Buy" consensus, Zacks Research recently downgraded the stock …

GH Research stock hits all-time high at 31.41 USD By Investing.com

GH Research PLC (GHRS) stock reached an all-time high of $31.41, marking a 146.9% increase over the past year, reflecting strong investor confidence and potential growth. The company, with a market capitalization of approximately $2.1 billion, is considered undervalued relative to its Fair Value …

GH Research PLC Stock 12‑Month Price Target Raised to $41.1, Implies 41% Upside

Analysts have raised the 12-month price target for GH Research PLC stock to $41.1, up from $39.9, implying a 41% potential upside from its August 5th closing price. The target is based on estimates from 10 analysts, with individual forecasts ranging from $31 to …

GH Research (NASDAQ:GHRS) Reaches New 12-Month High Following Earnings Beat

GH Research (NASDAQ:GHRS) recently hit a new 52-week high after reporting quarterly earnings that surpassed analyst expectations, with an EPS of negative $0.23 against an estimated negative $0.29. The clinical-stage biotech, focusing on psychedelic-inspired treatments for neuropsychiatric disorders, maintains a "Moderate Buy" consensus rating …

GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates

GH Research Releases Q2 2026 Financial Results

GH Research PLC reported a wider net loss of $15.1 million, or $0.23 per share, for Q2 2026, a 53.3% increase from the prior year, as the clinical-stage biopharmaceutical company continues to develop its depression treatment pipeline. The company is operating at a loss …

GH Research (Nasdaq: GHRS) grows cash to $362.7M as R&D spending rises

GH Research PLC reported a wider loss in the first half of 2026, reaching $34.1 million, despite increasing its cash, cash equivalents, and marketable securities to $362.7 million. The increase in loss is attributed to rising research and development (R&D) and general and administrative …

GHRS: GH001 achieves rapid, sustained TRD remission with fewer visits and robust IP protection

GH Research PLC (GHRS) announced that its drug candidate GH001 achieved rapid and sustained remission in Treatment-Resistant Depression (TRD) patients. The treatment has a short 11-minute psychoactive phase and demonstrated up to 73% remission at 6 months, while its unique clinic model significantly reduces …

FDA Says GH Research's Device Plans Appear Phase 3 Ready

GH Research (GHRS) reported its Q2 2026 financial results, including a net loss of $15.1 million and cash reserves of $362.7 million. The company announced that its GH001 program for treatment-resistant depression is progressing, with the FDA indicating that CMC and device plans appear …

GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development work

GH Research reported a widened net loss of USD 34.11 million for the first half of 2026, primarily due to increased operating costs. Research and development expenses significantly rose to USD 24.78 million, driven by clinical and technical development work on GH001. Despite the …

Is GH Research (GHRS) Fully Valued Following Its Share Price Surge?

GH Research (GHRS) has seen significant share price growth, with a 104.29% return over the last year, driven by its depression treatment pipeline. Despite ongoing losses and no current revenue, the stock trades at a high price-to-book multiple of 7.3x, suggesting it is overvalued …

(GHRS) Volatility Zones as Tactical Triggers

This article from Stock Traders Daily analyzes Gh Research Plc (NASDAQ: GHRS) using AI models to provide trading strategies and risk management parameters. It identifies weak near-term sentiment but potential for shifts in mid and long-term outlook, noting a compelling upside potential due to …

GH Research (GHRS) to Announce Earnings on Thursday

GHRS|GH Research PLC|Price:27.830|Chg%:+0.550

GH Research PLC (GHRS) saw its stock rise by 2.02% to $27.830. The company, focused on psychiatric and neurological disorders, is developing 5-MeO-DMT therapies, including GH001 which has completed Phase 1/2 clinical trials for Treatment Resistant Depression. Analysts currently rate GHRS as a "Buy" …

GH Research PLC (GHRS) Institutional Confidence

This article provides details on the institutional confidence in GH Research PLC (GHRS), listing key institutional shareholders and their recent activity. It shows several institutions holding significant shares, with some increasing their stakes and others decreasing or maintaining their positions. The overview includes the …

Wells Fargo Initiates GH Research at Overweight With $44 Price Target

Wells Fargo has initiated coverage of GH Research PLC (GHRS) with an "Overweight" rating and a price target of $44. The article highlights GH Research's clinical-stage biopharmaceutical focus on developing mebufotenin therapies for treatment-resistant depression (TRD), including its GH001 inhalable product candidate and GH002 …

Troluce Capital Advisors LLC Raises Holdings in GH Research PLC $GHRS

GH Research PLC (GHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of GH Research PLC (GHRS), including support and resistance levels, various technical indicators, and moving averages. It details indicator values for MACD, RSI, KDJ, ATR, CCI, WR, TRIX, and StochRSI, as well as multiple moving averages (MA5, MA10, …

GH Research PLC Revenue Breakdown – NASDAQ:GHRS

This article provides a financial breakdown for GH Research PLC (NASDAQ:GHRS) on TradingView. It highlights that no specific revenue data or detailed financials are available on this particular page, although it outlines access to various financial statements and fundamental statistics for the company. The …

GHRS: GH Research PLC Latest Stock Price, Analysis, News and Trading Ideas

This page provides the latest stock information for GH Research PLC (GHRS), including its current price, market capitalization, volume, and 52-week high/low. It also highlights recent news related to mental health treatments, specifically mentioning a depression drug clearing a hurdle, and features top discussions …

Price-Driven Insight from (GHRS) for Rule-Based Strategy

This article provides a price-driven analysis of Gh Research Plc (NASDAQ: GHRS) for developing a rule-based trading strategy. It highlights strong sentiment supporting an overweight bias and identifies key support and resistance levels across multiple time horizons. The analysis includes AI-generated institutional trading strategies …